Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
gatipotuzumab + tomuzotuximab
- Development stage
- Unknown
- Lead developer
- Pentixapharm
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Gatipotuzumab + tomuzotuximab is a combination of two humanized monoclonal antibodies developed for the treatment of advanced solid tumors. Gatipotuzumab targets the tumor-associated epitope of mucin-1 (TA-MUC1), a glycoepitope present on many carcinomas, enabling tumor-specific binding and immune activation. Tomuzotuximab is an immune-enhanced, glycooptimized monoclonal antibody against the epidermal growth factor receptor (EGFR), designed to improve antibody-dependent cellular cytotoxicity (ADCC) and reduce allergic reactions compared to cetuximab. The combination aims to exploit potential synergistic effects by dual targeting TA-MUC1 and EGFR, both implicated in epithelial tumor progression, with enhanced ADCC activity observed preclinically. Both antibodies were developed by Glycotope[5][6][8].
- Other names
- anti-TA-MUC1anti-TA-MUC-1anti-TA-MUC 1anti-EGFR antibody
02
Targets
TA-MUC1 (Tumor-associated MUC1)EGFR (Epidermal growth factor receptor)
Beyond the preview
Go deeper on gatipotuzumab + tomuzotuximab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on gatipotuzumab + tomuzotuximab.